Mira Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.18, missing the estimate of USD -0.08.

EBIT: As of FY2025 Q3, the actual value is USD -1.333 M.

Segment Revenue

• The company reported no revenue for the three and nine months ended September 30, 2025, and 2024.

Operational Metrics

• Net Loss: The net loss for the three months ended September 30, 2025, was $1,137,673, compared to $2,043,867 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $4,459,164, compared to $5,452,963 in 2024.
• Operating Costs: Total operating costs for the three months ended September 30, 2025, were $1,316,985, down from $2,081,619 in 2024. For the nine months ended September 30, 2025, operating costs were $4,668,285, compared to $5,580,527 in 2024.
• General and Administrative Expenses: These expenses were $904,346 for the three months ended September 30, 2025, compared to $1,014,223 in 2024. For the nine months ended September 30, 2025, the expenses were $3,445,045, compared to $3,136,393 in 2024.
• Research and Development Expenses: R&D expenses were $412,639 for the three months ended September 30, 2025, compared to $1,067,396 in 2024. For the nine months ended September 30, 2025, R&D expenses were $1,223,240, compared to $2,444,134 in 2024.

Cash Flow

• Operating Cash Flow: The net cash used in operating activities for the nine months ended September 30, 2025, was - $3,526,632, compared to - $3,755,576 in 2024.
• Financing Activities: Net cash provided by financing activities was $3,335,240 for the nine months ended September 30, 2025, compared to $3,297,570 in 2024.

Unique Metrics

• Unrealized Gain on Short-term Investments: An unrealized gain of $176,056 was recorded on September 30, 2025, due to the increase in value of Telomir Pharmaceuticals, Inc. shares received in the SKNY acquisition.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue the development of its drug candidates, Ketamir-2 and MIRA-55, with ongoing and planned clinical trials. A Phase 2a study for Ketamir-2 in chemotherapy-induced peripheral neuropathy is planned for the first half of 2026.
• Non-Core Business: The acquisition of SKNY Pharmaceuticals, Inc. is expected to enhance the company’s pipeline with SKNY-1, a preclinical-stage drug candidate targeting metabolic and behavioral modulation.
• Priority: The company emphasizes the need for additional funding to support ongoing operations and future clinical trials, with plans to secure capital through public equity offerings and strategic transactions.